Los Angeles Convention Center
Los Angeles, CA
May 16-20, 2023

Promega Corporation  

Discover Promega. Support cell & gene therapy development.

With a portfolio of >4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega provides a variety of solutions to meet the fast-growing demands in cell and gene therapy development. Our solutions include state-of-the-art functional reporter bioassays, cell health assays and simple and fast Lumit™ cytokine immunoassays for bioactivity and potency testing, bioassay qualification services for biologics manufacturing and QC lot release, advanced bioanalytical tools for mass spec analysis, automated and manual systems and reagents for DNA/RNA extraction from any sample type, STR analysis kits together with benchtop capillary electrophoresis (CE) instrument Spectrum Compact CE system for cell line authentication, and various polymerases and master mixes for PCR and qPCR testing and much more. To learn more visit www.promega.com.

Brands: Fueled by curiosity. Powered by exploration. A global biotechnology leader, providing innovative solutions & technical support to life scientists in academic & industrial settings for over 40 years.


  • AAV-NanoLuc®-HaloTag® Reporter
    The sensitive and versatile AAV-NanoLuc®-HaloTag® Dual Reporter System can be used for a variety of applications including novel serotype screening, determining in vivo biodistribution and neutralizing antibody detection....

  • Measure In Vitro Cell Transduction (Infectivity)

    Transducing cell lines with AAV-NanoLuc®-HaloTag® reporter for each AAV serotype allows you to measure the selectivity of each AAV serotype for the cell line transduced. If transduction is successful, the expressed NanoLuc® luciferase will produce a luminescent signal in the presence of a substrate. The resulting luminescent signal intensity is proportional to the transduction efficiency of AAV.

    Detecting In Vivo Tropism and Biodistribution with NanoLuc® Luciferase

    NanoLuc® luciferase and the Nano-Glo® Fluorofurimazine In Vivo Substrate (FFz) offer a new reporter option for AAV in vivo biodistribution studies. Optimized specifically for in vivo detection of NanoLuc® luciferase, the Nano-Glo® FFz Substrate is an aqueous soluble detection reagent with increased substrate bioavailability that leads to bright, stable signals. Nano-Glo® FFz has handling requirements compatible with in vivo workflows, offers flexible delivery options and the substrate specificity allows NanoLuc® and firefly luciferases to be used together for dual-luciferase imaging studies. 

    AAV Neutralizing Antibody (NAb) Assay

    Neutralizing antibodies (anti-AAV antibodies) are present in the serum of human or animals previously exposed to AAV. The NanoLuc® luciferase-based NAb assay measures transduction inhibition of AAV resulting from the presence of anti-AAV antibodies in human serum. The antibodies block viral entry into the cells and prevent expression of NanoLuc® luciferase. Reduction in luminescent signal suggests that anti-AAV antibodies are present in the human serum.